Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 3/20 | 0.63 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.45 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2746892 | 0.89 | NNMT (0.61) | NNMTEPHX2SMN1; SMN2DEGS1 | |
| SCHEMBL855055 | 0.88 | NNMT (0.47) | NNMTEPHX2SMN1; SMN2DEGS1KDR | |
| SCHEMBL7090884 | 0.85 | DEGS1 (0.47) | NNMTSMN1; SMN2DEGS1KDRNPC1 | |
| SCHEMBL3465475 | 0.81 | NNMT (0.69) | NNMTEPHX2SMN1; SMN2 | |
| SCHEMBL5734042 | 0.80 | NNMT (0.58) | NNMTEPHX2SMN1; SMN2GRIN2B | |
| SCHEMBL1163357 | 0.80 | PTGS1 (0.54) | SMN1; SMN2DEGS1KDRNPC1RAB9A | |
| SCHEMBL14185002 | 0.80 | NNMT (0.67) | NNMTEPHX2SMN1; SMN2 | |
| SCHEMBL2746891 | 0.79 | NNMT (0.61) | NNMTEPHX2SMN1; SMN2RAB9A | |
| SCHEMBL6058855 | 0.79 | GRIN2B (0.49) | NNMTEPHX2SMN1; SMN2DEGS1KDR | |
| SCHEMBL28157252 | 0.79 | NNMT (0.70) | NNMTEPHX2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120208813-A1 | 3-CARBAMOYL-2-PYRIDONE DERIVATIVES | SHIONOGI & CO., LTD. | 2012-08-16 | — | — | US | disclosed |
| US-8178681-B2 | methyl 3-methyl-2-{[2-oxo-1-(2-oxo-ethyl)-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-butyrate; cannabinoid receptor agonist; antiinflammatory agent, immunostimulant, analgesic; atopic dermatitis; excellent in photostability, and have excellent transdermal and oral absorbency | SHIONOGI & CO., LTD. (JP) | 2012-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208813-A1 | 3-CARBAMOYL-2-PYRIDONE DERIVATIVES | CNR2, CNR1, HRH4 | NNMT 2607/4885EPHX2 1166/4885SMN1; SMN2 4550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.